Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Colorectal Cancer

SB Pharma

Status and phase: Unknown; Phase 2

Conditions: Colorectal Cancer

Treatments: Drug: SB injection

Study type: Interventional

Funder types: Industry

Identifiers

NCT01305980

SB injection-C002

Details and patient eligibility

About

The purpose of this study is to determine efficacy of SB injection in Colorectal Cancer.

Full description

All eligible patients will receive SB injection therapy for 6 cycles (14~21 days for each cycle). Efficacy will be evaluated every 3 cycles.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age of 18years or over

• Patients who had failed more than 1 cycle of standard therapy with advanced or metastatic stage and with measurable lesions

• Life expectancy >/= 5 months

• Not available to any of resectable surgery or radiotherapy

• Patients with adequate organ(e.g. heart, kidney, liver)and bone marrow function, as defined by

  1. Absolute neutrophil count >/= 1.0 x 10^9/L, Platelet count >/= 75 x 10^9/L
  2. Total bilirubin < 2.0 mg/dL
  3. Aspartate Aminotransferase and/or Aspartate Aminotransferase < 5 x Upper Limit Normal
  4. creatinine < 2 x Upper Limit Normal

• ECOG status 0 to 2

• Female volunteers admitted to the study must be using a reliable means of contraception and must have a negative blood or urine pregnancy test at least 7days ago

• Patients or their legal representatives who have signed the informed consent form.

Exclusion criteria

• Have inflammatory bowel diseases
• Have severe diarrhea or ileus
• Previous total colectomy
• Have ileostomy
• Known brain or spinal cord metastases
• Patients who have received chemotherapy within the previous 4 weeks
• Patients who have received radiotherapy related tp colorectal cancer within 4weeks
• Patients who have participated in other clinical study within the previous 4weeks
• Pregnancy or lactation period
• Human Immunodeficiency Virus antibody (+)
• Have active infection or serious concomitant systemic disorder incompatible with the study
• Clinically hypertension or diabetes mellitus not well controlled with medication
• Clinically significant cardiac disease(congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias) or myocardial infarction
• Presence or history of malignancy other than colorectal cancer within 5years
• Have severe Neurologic or psychological disorder
• Patients who have history of allergy with this investigational drug(SB injection)
• Obvious cognitive or physical impairment that would prevent participation

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)